| __timestamp | Amneal Pharmaceuticals, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 106735000 | 12122000 |
| Thursday, January 1, 2015 | 136870000 | 13380000 |
| Friday, January 1, 2016 | 204747000 | 21221000 |
| Sunday, January 1, 2017 | 191938000 | 26887000 |
| Monday, January 1, 2018 | 210451000 | 27863000 |
| Tuesday, January 1, 2019 | 202287000 | 55908000 |
| Wednesday, January 1, 2020 | 190585000 | 59392000 |
| Friday, January 1, 2021 | 209563000 | 69012000 |
| Saturday, January 1, 2022 | 200046000 | 36082000 |
| Sunday, January 1, 2023 | 167778000 | 24537000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Amneal Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have demonstrated contrasting strategies in their R&D investments. Amneal's R&D expenses have consistently outpaced Ligand's, with Amneal investing nearly five times more on average. This significant investment reflects Amneal's commitment to expanding its product pipeline and enhancing its market position.
From 2014 to 2023, Amneal's R&D spending peaked in 2018, with a 97% increase from 2014, while Ligand saw its highest expenditure in 2021, marking a 469% rise from 2014. These trends highlight the dynamic nature of pharmaceutical innovation, where strategic R&D investments can lead to groundbreaking treatments and substantial market growth. As the industry evolves, the focus on R&D remains a critical driver of success and sustainability.
Research and Development: Comparing Key Metrics for Novo Nordisk A/S and Ligand Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Comparing Innovation Spending: Sarepta Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Madrigal Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated Allocate Funds
Comparing Innovation Spending: ADMA Biologics, Inc. and Ligand Pharmaceuticals Incorporated
Amneal Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.: Strategic Focus on R&D Spending
Analyzing Cost of Revenue: Amneal Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated
R&D Insights: How Amneal Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Amneal Pharmaceuticals, Inc. and MiMedx Group, Inc.
Comparing Innovation Spending: Perrigo Company plc and Ligand Pharmaceuticals Incorporated
Research and Development Investment: Ligand Pharmaceuticals Incorporated vs BioCryst Pharmaceuticals, Inc.